Deutsche Bank on February 10, 2026 kept a Hold on Hims & Hers Health, Inc. and cut the price target to $31 from $42. The HIMS analyst rating action followed updated revenue and margin assumptions. Investors should weigh the maintained Hold against the new price target and recent price movement, including a 5.98% drop equal to $1.09 since the call.
HIMS analyst rating: Deutsche Bank maintains Hold and lowers price target
Deutsche Bank kept a Hold on Hims & Hers on February 10, 2026 while lowering the price target to $31 from $42. The firm cited weaker near-term visibility and adjusted estimates for growth and margins. Read the original note on TheFly for details source.
What the HIMS analyst rating means for investors
A maintained Hold signals Deutsche Bank sees limited upside relative to risk. Investors should view the rating as a call for selective patience, not immediate selling. The new $31 target sets a clearer short-term valuation anchor and raises emphasis on execution and revenue visibility.
Price impact and market context from the HIMS analyst rating
Deutsche Bank’s update coincided with a 5.98% move, about $1.09, reflecting investor reaction to the lower target. With a market cap of $3,778,607,556, Hims & Hers sits in a size bracket where analyst tone can sway short-term flows and option positioning.
Historical analyst coverage and recent peers mentioning the HIMS analyst rating
Hims & Hers has seen steady analyst attention from firms including TD Cowen and Leerink Partners, which recently reiterated Hold/Market Perform views. TD Cowen kept a $30 target in recent coverage source. That history frames Deutsche Bank’s move as another cautious check rather than an outlier.
How to interpret the HIMS analyst rating and price target change
A lowered price target narrows upside expectations and raises the bar for upcoming catalysts. Investors should compare Deutsche Bank’s assumptions with company guidance and product cadence. Use the rating as one input in position sizing and risk management, especially ahead of key product or earnings events.
Meyka AI view and proprietary grade on the HIMS analyst rating
Meyka AI rates HIMS with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our AI-powered market analysis platform tracks rating shifts in real time and flags that Deutsche Bank’s maintained Hold plus lower target tightens expected returns.
Final Thoughts
Deutsche Bank’s Hold on Hims & Hers on February 10, 2026, with a cut to $31 from $42, is a clear signal of moderated near-term expectations. The HIMS analyst rating update matters because it resets a visible price anchor and influences short-term flows for a company with a $3,778,607,556 market cap. For investors, the practical takeaway is to treat the call as guidance to assess catalysts and margins rather than as a binary trade instruction. Compare Deutsche Bank’s assumptions with other recent firm views, including TD Cowen and Leerink Partners, and watch upcoming revenue prints for confirmation. Remember, Meyka AI rates HIMS with a grade of B+, which blends benchmark and sector analysis with analyst consensus. These grades are not guarantees and are not financial advice. Use the HIMS analyst rating as one input in a diversified decision process and consider position sizing around confirmed operational improvements.
FAQs
What did Deutsche Bank change in the HIMS analyst rating on Feb 10, 2026?
Deutsche Bank maintained a Hold rating and lowered the price target to $31 from $42 on February 10, 2026. The update tightened near-term expectations and followed revised revenue and margin assumptions.
How should investors use the HIMS analyst rating and new price target?
Treat the HIMS analyst rating as a valuation anchor. Use the $31 target to stress-test scenarios, prioritize catalysts, and size positions rather than as a strict buy or sell trigger.
Does the HIMS analyst rating affect short-term stock moves?
Yes. Deutsche Bank’s maintained Hold and lower target coincided with a 5.98% move, about $1.09, showing ratings can sway short-term flows, especially for mid-cap names like Hims & Hers.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
